Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono/ Domain Parkinson's deal

Merck Serono and Domain Therapeutics are to partner in a deal to develop drugs to target neurodegenerative diseases such as Parkinson's

Merck Serono - Merck's biopharmaceutical division - and Domain Therapeutics are to partner in a deal to develop drugs to target neurodegenerative diseases such as Parkinson's disease.

The agreement will see France-based biopharmaceutical company, Domain, offer Merck access to a portfolio of optimised investigational compounds. In return, Domain will receive €2m in an upfront payment, with up to €132m available in milestone payments for the first two products to be developed.

The compounds to be developed are positive allosteric modulators for metabotropic glutamate receptor 4 (mGluR4). Glutamate receptors are a member of the G-protein coupled receptor (GPCR) family, a group of proteins which transmit signals into cells, and are seen as therapeutic targets for Parkinson's disease.

"We are pleased to have the opportunity to work with Domain Therapeutics, which has developed great expertise in the GPCR area," said Bernhard Kirschbaum, executive vice president for global research and development at Merck Serono. "This partnership with Domain Therapeutics reflects our long-term commitment to develop new treatments for neurodegenerative diseases."

Pascal Neuville, CEO, Domain Therapeutics, said: "This agreement is a validation of Domain Therapeutics' business model of addressing difficult GPCRs and partnering compounds, with a significant deal, at an early stage of development."

17th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics